GlobeNewswire by notified

Transactions in Connection with Share Buy-back Program

Share

Company Announcement

COPENHAGEN, Denmark; April 2, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.

The share buy-back program is expected to be completed no later than December 16, 2024.

The following transactions were executed under the program from March 25, 2024 to March 29, 2024:

Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)
Accumulated through
last announcement
81,186165,554,609.26
March 25, 2024XCSE7,3862,064.44
CEUX5,1512,063.67
AQEU4812,065.08
TQEX8732,063.30
Total13,8912,064.1028,672,472.83
March 26, 2024XCSE7,3032,111.09
CEUX4,6832,109.90
AQEU4472,111.13
TQEX7542,105.86
Total13,1872,110.3727,829,417.54
March 27, 2024XCSE6,3302,097.36
CEUX5,1442,097.17
AQEU6742,098.12
TQEX7112,096.24
Total12,8592,097.2626,968,684.34
March 28, 2024XCSE0
CEUX0
AQEU0
TQEX0
Total00
March 29, 2024XCSE0
CEUX0
AQEU0
TQEX0
Total00
Total39,93783,470,574.71
Accumulated under the program121,123249,025,183.97

Details of each transaction are included as an appendix to this announcement.

Following these transactions, Genmab holds 981,465 shares as treasury shares, corresponding to 1.48% of the total share capital and voting rights.

The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Further details on the terms of the share buy-back program can be found in our company announcement no. 22 dated March 15, 2024.

About Genmab
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative, and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies, and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S., and Tokyo, Japan. For more information, please visit Genmab.com and follow us on LinkedIn and X.

Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect®and KYSO®.

Company Announcement no. 25
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Resume trading in SKAGEN and Storebrand funds21.5.2024 08:32:00 CEST | Press release

Lysaker, 21 May 2024 Trading in the below funds can be resumed today, after suspension on 17th May due to national holiday (Independence Day) in Norway. Regards Storebrand Asset Management AS Contacts: Kim Toftegaard Andreassen, Director, Kim.Toftegaard.Andreassen@storebrand.com Frode Aasen, Product Manager, fdc@storebrand.com Fund name and share classSymbolISINSKAGEN Focus ASKIFOANO0010735129SKAGEN Global ASKIGLONO0008004009SKAGEN Kon-Tiki ASKIKONNO0010140502SKAGEN m2 ASKIM2NO0010657356SKAGEN Vekst ASKIVEKNO0008000445Storebrand Indeks – Alle Markeder A5STIIAMNO0010841588Storebrand Indeks – Nye Markeder A5STIINMNO0010841570Storebrand Global ESG Plus A5STIGEPNO0010841604Storebrand Global Solutions A5STIGSNO0010841612Storebrand Global Multifactor A5STIGMNO0010841596 Storebrand is Norway's largest private asset manager with an AuM of around DKK 800 billions, and also a leading Nordic provider of sustainable pensions and savings. The company has been a global pioneer in ESG investing for o

Sydbank to acquire Coop Bank A/S21.5.2024 08:15:00 CEST | Press release

Company Announcement No 18/2024Peberlyk 4 6200 Aabenraa Denmark Tel +45 74 37 37 37 Sydbank A/S CVR No DK 12626509, Aabenraa sydbank.dk 21 May 2024 Dear Sirs Sydbank to acquire Coop Bank A/S Sydbank A/S and Coop amba have concluded an agreement to the effect that Sydbank will acquire Coop Bank A/S. Following the acquisition, Coop Bank A/S will become a wholly owned subsidiary of Sydbank A/S. In addition the agreement includes a partnership that will create attractive value propositions for the customers of Coop Bank A/S as well as for the other members of Coop Danmark. It is expected that the partnership will generate increased business volume at Coop Bank A/S. Purchase price The parties have agreed a price involving payment of the value of the equity at the date of acquisition plus DKK 89m. The cash purchase price cannot be finally calculated until the date of acquisition. The preliminary purchase price has been calculated at DKK 345m. Terms of acquisition The implementation of the ac

Sydbank A/S køber Coop Bank A/S21.5.2024 08:15:00 CEST | pressemeddelelse

Selskabsmeddelelse nr. 18/2024Peberlyk 4 DK-6200 Aabenraa Telefon +45 74 37 37 37 Sydbank A/S CVR-nr. DK 12626509, Aabenraa sydbank.dk 21. maj 2024 Sydbank A/S køber Coop Bank A/S Sydbank A/S og Coop amba har indgået aftale om, at Sydbank køber Coop Bank A/S. Efter overtagelsen vil Coop Bank A/S være et 100 pct. ejet datterselskab af Sydbank A/S. Aftalen omfatter også et partnerskab, der vil skabe attraktive værditilbud for såvel kunderne i Coop Bank A/S og Coop Danmarks øvrige medlemmer. Partnerskabet forventes at kunne give øget forretningsomfang i Coop Bank A/S. Købesum Der er parterne imellem aftalt en handelspris, hvor der betales for værdien af egenkapitalen pr. overtagelsesdagen tillagt 89 mio. kr. Den kontante købesum kan først endeligt opgøres på overtagelsesdagen. Den foreløbigt opgjorte købesum udgør 345 mio. kr. Betingelser for handlen Gennemførelse af handlen er betinget af: Finanstilsynets godkendelseKonkurrence- og Forbrugerstyrelsens godkendelse Betingelserne forventes

Bedford Metals Completes Close Lake Uranium Project Option Agreement21.5.2024 08:00:00 CEST | Press release

VANCOUVER, British Columbia, May 21, 2024 (GLOBE NEWSWIRE) -- Bedford Metals Corp. (TSX-V: BFM) (the “Company” or “Bedford”) is pleased to announce that following a successful diligence review, it has elected to enter into a definitive option agreement (the “Agreement”) with an arm’s-length party pursuant to which it has been granted the rights to acquire the Close Lake Uranium Project, a further addition to the Company’s mineral project portfolio. The Close Lake Uranium Project lies on the eastern side of the Athabasca Basin, adjoining claims held by Cameco Corporation, the largest uranium producer in the world. The Project is approximately 245 hectares and lies within the primary exploration corridor, which hosts the Keys Lake mine, the Cigar Lake Mine and the McArthur River Mine. The property is accessible through a network of roads and trails. After completing due diligence, Bedford elected to proceed with a definitive agreement, recognizing the potential of the Project to contribu

Progress on share buyback programme21.5.2024 08:00:00 CEST | Press release

Progress on share buyback programme ING announced today that, as part of our €2.5 billion share buyback programme announced on 2 May 2024, the company repurchased 14,758,595 shares during the week of 10 May 2024 up to and including 17 May 2024. The shares were repurchased at an average price of €16.25 for a total amount of €239,869,875.39. For detailed information on the daily repurchased shares, individual share purchase transactions and weekly reports, see the ING website at www.ing.com/investorrelations. In line with the purpose of the programme to reduce the share capital of ING, the total number of shares repurchased under this programme to date is 44,306,341 ordinary shares at an average price of €16.09 for a total consideration of €712,919,917.39. To date approximately 28.52% of the maximum total value of the share buyback programme has been completed. Note for editors For more on ING, please visit www.ing.com. Frequent news updates can be found in the Newsroom or via X @ING_new

HiddenA line styled icon from Orion Icon Library.Eye